Verzenio/Verzenios (abemaciclib) vs Xeloda ()
Verzenio/Verzenios (abemaciclib) vs Xeloda ()
Verzenio (abemaciclib) is a CDK4/6 inhibitor used primarily in combination with hormonal therapies for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, focusing on cell cycle regulation to prevent cancer cell growth. Xeloda (capecitabine) is an oral chemotherapy drug that is converted into 5-fluorouracil (5-FU) in the body, used to treat various types of cancer including breast, colorectal, and gastric cancers by interfering with DNA synthesis and function, leading to cell death. The choice between Verzenio and Xeloda would depend on the specific type and stage of cancer, previous treatments, potential side effects, and the overall health profile of the patient, necessitating a personalized approach and consultation with an oncologist.
Difference between Verzenio/Verzenios and Xeloda
Metric | Verzenio/Verzenios (abemaciclib) | Xeloda () |
---|---|---|
Generic name | Abemaciclib | Capecitabine |
Indications | HR-positive, HER2-negative advanced or metastatic breast cancer | Metastatic colorectal cancer, metastatic breast cancer |
Mechanism of action | CDK4 & CDK6 inhibitor | Antimetabolite, thymidine phosphorylase activation |
Brand names | Verzenio, Verzenios | Xeloda |
Administrative route | Oral | Oral |
Side effects | Diarrhea, neutropenia, nausea, abdominal pain, infections | Hand-foot syndrome, diarrhea, nausea, vomiting, fatigue |
Contraindications | Hypersensitivity to abemaciclib or excipients | Hypersensitivity to capecitabine or fluorouracil |
Drug class | Antineoplastic agent, kinase inhibitor | Antimetabolite, fluoropyrimidine |
Manufacturer | Eli Lilly and Company | Roche |
Efficacy
Verzenio (Abemaciclib) in the Treatment of Breast Cancer
Verzenio, also known by its generic name abemaciclib, is a targeted therapy medication used in the treatment of certain types of breast cancer. Specifically, it is indicated for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Abemaciclib is a cyclin-dependent kinase (CDK) 4 and 6 inhibitor that works by interfering with the proliferation of cancer cells. Clinical trials have demonstrated that when used in combination with an aromatase inhibitor or fulvestrant, Verzenio can significantly improve progression-free survival in patients with this subtype of breast cancer. Additionally, it has shown efficacy as a monotherapy in patients who have previously received hormone therapy and chemotherapy.
Xeloda (Capecitabine) in the Treatment of Breast Cancer
Xeloda, with the generic name capecitabine, is an oral chemotherapy drug that is used to treat breast cancer among other types of cancer. It is a prodrug that is converted into 5-fluorouracil (5-FU) in the body, which then acts to inhibit DNA synthesis and slow the growth of cancer cells. Xeloda is often used in the treatment of metastatic breast cancer, particularly after failure of anthracycline-containing chemotherapy. In clinical studies, capecitabine has shown effectiveness in improving overall survival rates and reducing the risk of disease progression when compared to other chemotherapy agents. It is also used in combination with other drugs, such as docetaxel, to enhance therapeutic outcomes.
Combination Therapy and Sequential Treatment
For many patients with advanced breast cancer, a combination of Verzenio and Xeloda may be considered, depending on the specific characteristics of their disease and prior treatments they have received. The rationale behind combination therapy is to target cancer cells through different mechanisms, potentially increasing the efficacy of treatment. Additionally, sequential treatment, where one drug is used after the other, is a common approach in the management of breast cancer to overcome resistance to therapy and to manage the side effects associated with treatment.
Conclusion
Both Verzenio and Xeloda have shown significant efficacy in the treatment of certain types of breast cancer, offering hope for improved outcomes in patients with this disease. The choice of therapy, whether it be monotherapy with either drug or a combination of both, is based on a variety of factors including the specific subtype of breast cancer, previous treatments, and the patient's overall health. Clinical trials continue to refine the optimal use of these medications to provide the best possible benefit for patients with breast cancer.
Regulatory Agency Approvals
Verzenio/Verzenios
Xeloda
Access Verzenio/Verzenios or Xeloda today
If Verzenio/Verzenios or Xeloda are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us